Videos

Two experts offer perspectives on the importance and state of cardiovascular health in women.

Pending FDA decision, the Viaskin Peanut patch would be considered for lengthier benefit studies.

Anne Dixon, MD, explains how it took 6 years to update recommendations for new asthma therapies.

The epicutaneous immunotherapy for peanut allergy is continuing discussions with the FDA. What is its potential in allergic care?

Rodney Wilson, spokesperson from the American Red Cross, offers some final thoughts on how providers can encourage blood donations among their patients.

A spokesperson from American Red Cross discusses the importance of National Blood Donor Month and the challenges faced during the COVID-19 pandemic.

Dr. Matthew Brams presented new data showing the efficacy of CTx-1301 for ADHD.

CTx-1301's formulation enables 3 different doses within 1 pill for ADHD.

Researchers are prepared a phase 3 trial testing the treatment in adults with ADHD.

The role of many in psychiatry has changed during the COVID-19 pandemic.

A pair of researchers present plans to improve collaboration with other professionals in ADHD.

Dr. David Goodman predicts some patients may improve their organizational skills during the pandemic.

Adults with ADHD may face a number of challenges during the ongoing pandemic.

The virtual conference will feature researchers from the US, Germany, Japan, and more.

A conversation on how associations between the chronic conditions have become better understood in 10 years.

Peter Lio, MD, discusses conventional therapeutic options for pruritus.

ADM Giroir, MD, discusses additional examples of efforts to optimize sickle cell care.

The US Assistant Secretary for Health provides a top-down, government-level perspective on how sickle cell care has advanced in recent years.

Peter Lio, MD, discusses the various underlying causes behind itch.

The TARGET-NASH study seeks to shed light on treatment for NASH and NAFLD.

Amputations have increased 30% among diabetic patients since the pandemic began.

There is concern over whether or not patients are adhering to their treatment during the pandemic.

Dr. Giorgino discusses how combining SGLT2 Inhibitors and GLP-1RA could be combined for treating type 2 diabetes.